Brief: Isofol Reports Data From Agent Study

Isofol Medical AB (publ)

07/09/2022 12:06

Sept 7 (Reuters) - AstraZeneca PLC  AZN.L :
    * REPORTS DATA FROM THE AGENT STUDY
    * TODAY REPORTED DATA FROM AGENT STUDY THAT FORMED BASIS FOR
ITS
ASSESSMENT THAT IT WAS NOT JUSTIFIED TO CONTINUE STUDY
    * WILL CONTINUE TO COLLECT AND REVIEW DATA RELATED TO, AMONG
OTHER
AREAS, SUBGROUPS AND GENE EXPRESSION, IN ORDER TO IDENTIFY
POSSIBLE COMMERCIAL VALUE
    * DATA HAS SO FAR FAILED TO SHOW ANY CONCRETE RESULTS OF
VALUE,
WHICH MEANS SEVERELY LIMITED COMMERCIAL POTENTIAL
    * AGENT STUDY WILL BE TERMINATED IN ACCORDANCE WITH
APPLICABLE
ETHICAL CONSIDERATIONS AND REGULATORY REQUIREMENTS, WHICH WILL
OCCUR DURING AUTUMN
    * PARALLEL TO THIS, ISOFOL'S BOARD OF DIRECTORS WILL
EVALUATE
POSSIBLE COURSES OF ACTION TO SECURE GREATEST POSSIBLE VALUE FOR
ISOFOL'S SHAREHOLDERS

Source text for Eikon:  ID:nWkr14xDN1 
Further company coverage:  AZN.L 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))